
The Dose
FDA Sends 30 Warning Letters to Telehealth Companies Over Misleading GLP-1 Claims
The FDA cracked down on telehealth companies making false claims about compounded GLP-1 alternatives, sending 30 warning letters in its biggest enforcement action yet.
GLP1 Clinics News Desk·

